Drugs / QPX9003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04808414 | Jun 2021 → Jul 2022 | bacterial infectious disease | Qpex Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QPX9003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04808414 ↗ |
| Route | Intravenous | “This Phase 1 study will assess the safety, tolerability and pharmacokinetics of single and multiple IV administered ascending doses (SAD/MAD) of IV QPX9003 in healthy adult subjects.” NCT04808414 ↗ |